Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of TAS3351 in EGFR-mutant advanced non-small cell lung cancer
NL-OMON60625Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TAS3351 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Taiho Oncology. Primary endpoints: Safety and dose-limiting toxicities and Objective response rate by independent central review. Started Aug 2024; status: completed.
02
Drugs
TAS3351
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60625.